APA (7th ed.) Citation

Ciracì, P., Germani, M., Pietrantonio, F., Manca, P., Lonardi, S., Busico, A., . . . Salvatore, L. (2026). Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: The PARERE study by GONO. Annals of Oncology, 37(1), 79. https://doi.org/10.1016/j.annonc.2025.10.002

Chicago Style (17th ed.) Citation

Ciracì, P., et al. "Re-treatment with Panitumumab Followed by Regorafenib Versus the Reverse Sequence in Chemorefractory Metastatic Colorectal Cancer Patients with RAS and BRAF Wild-type Circulating Tumor DNA: The PARERE Study by GONO." Annals of Oncology 37, no. 1 (2026): 79. https://doi.org/10.1016/j.annonc.2025.10.002.

MLA (9th ed.) Citation

Ciracì, P., et al. "Re-treatment with Panitumumab Followed by Regorafenib Versus the Reverse Sequence in Chemorefractory Metastatic Colorectal Cancer Patients with RAS and BRAF Wild-type Circulating Tumor DNA: The PARERE Study by GONO." Annals of Oncology, vol. 37, no. 1, 2026, p. 79, https://doi.org/10.1016/j.annonc.2025.10.002.